New release of a report about the commercial insight of anti-hormonal cancer therapies by Marketsensus 

by Michael Fu Wednesday, November 10, 2010
Marketsensus has just released a report about the commercial insight of anti-hormonal cancer therapies. Its main topic is about leading brands striving to minimize generic sales erosion.

Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $7.0 billion in the seven major pharmaceutical markets in 2009.

Scope

*In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot

*Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019

*Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

*Evaluation of the strategies of leading players in the antihormonals market

Highlights

The antihormonals market was worth $7.0 billion in 2009 across the seven major pharmaceutical markets. Datamonitor forecasts the antihormonals market will shrink marginally in the forecast period 20092019, at a CAGR of negative 0.7%.

In 2019 the top three brands in terms of forecast sales will be Arimidex, Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position.

In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Reasons to Purchase

*Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019

*Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth

*Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot.


COMMERCIAL INSIGHT: ANTIHORMONAL CANCER THERAPIES - LEADING BRANDS STRIVE TO MINIMIZE GENERIC SALES EROSION
http://www.marketsensus.com/commercial-insight-antihormonal-cancer-therapies-leading-brands-strive-minimize-generic-sales-erosion-p-95754.html



About Marketsensus:
Marketsensus is a leading market research services company distributing reports, newsletters, directories, databases, subscription services, country and/or company profiles and custom research in over 130 industry segments from over 30 of the worlds leading firms. Since 2005, they have recommended market research and helped clients centralize and streamline their research procurement.
Contact details:
Josephine Jenno
Director
+852 25224221
www.marketsensus.com

0    submitted by Michael Fu
Read More Press Releases

SKS Ispat& Power Ltd commissions first 300-MW power unit of their 1,200-MW RaigarhPower Plant

How a Bodybuilding Diet Can Help Build Muscle Naturally

Low Carb Diet Report Casts Light On New Research Findings

Increase in the number of student visa is trending nowadays

Wiwigo Technologies: First of its kind selfie campaign takes place in moving Delhi-Chandigarh Shatabdi

An important day in real estate sector

Leonard Kim to Appear on Critical Mass Radio Show

Nishan Kohli's recent exhibition on photography

CIMR-PU Esteemed Globally—SAARC DESIMGOW Moderator at NPA Venerated for High Contour-profiles.

Lilanie Kadirgamar Geiger dedicates cookbook to late mother

Get press releases by email